Ischemix Announces Positive Top Line Data From Phase 2a Clinical Trial Of CMX-2043 For The Prevention Of Peri-Operative Ischemia-Reperfusion Injury

Ischemix today announced positive top line data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury. The trial achieved its primary endpoint of safety with CMX-2043 demonstrating a favorable safety profile at all doses, consistent with the Phase 1 data. Additionally, although the trial was not powered to show statistical differences in efficacy, CMX-2043 demonstrated positive trends in all secondary efficacy endpoints and achieved statistically significant benefits in a key endpoint measure of cardiac health...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/r-r7YcEMlNU/228993.php

fitness exercise